Stay updated on LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial

Sign up to get notified when there's something new on the LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:59:22.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the evaluation of the maximum tolerated dose (MTD) and toxicities of the study drug LMB-100 administered by normothermic, intrapleural perfusion in participants with mesothelin-positive MPM or MPE from cancers expressing mesothelin.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:04.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers look for individuals who meet certain health conditions or have undergone specific prior treatments. The new criteria include histologically confirmed mesothelin-positive malignancy and other specific health requirements.
    Difference
    33%
    Check dated 2024-05-22T21:15:56.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:54:24.000Z thumbnail image

Stay in the know with updates to LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial page.